Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun 1;17(e2):e356-e364.
doi: 10.1136/jnis-2024-022467.

Endovascular therapy versus medical management in isolated anterior cerebral artery acute ischemic stroke: a multinational multicenter propensity score-weighted study

Hamza Adel Salim #  1   2 Benjamin Pulli #  3 Vivek Yedavalli #  4 Fathi Milhem  5 Basel Musmar  6 Nimer Adeeb  7 Dhairya A Lakhani  8 Muhammed Amir Essibayi  9 Jeremy Josef Heit  3 Tobias D Faizy  10 Kareem El Naamani  6 Nils Henninger  11 Sri Hari Sundararajan  12 Anna Luisa Kuhn  13 Jane Khalife  14 Sherief Ghozy  15 Luca Scarcia  16 Leonard Ll Yeo  17 Benjamin Yq Tan  17   18 Robert W Regenhardt  5 Nicole M Cancelliere  19 Aymeric Rouchaud  20 Jens Fiehler  21 Sunil A Sheth  22 Ajit S Puri  13 Christian Dyzmann  23 Marco Colasurdo  24 Leonardo Renieri  25 João Pedro Filipe  26 Pablo Harker  27 Răzvan Alexandru Radu  28 Mohamad Abdalkader  29 Piers Klein  29 Thomas R Marotta  19 Julian Spears  19 Takahiro Ota  30 Ashkan Mowla  31 Pascal Jabbour  6 Arundhati Biswas  32 Frédéric Clarençon  33 James E Siegler  14 Thanh N Nguyen  29 Ricardo Varela  34 Amanda Baker  9 David Altschul  9 Nestor Gonzalez  35 Markus A Möhlenbruch  36 Vincent Costalat  28 Benjamin Gory  37   38 Paul Stracke  39 Constantin Hecker  40 Gaultier Marnat  41 Hamza Shaikh  14 Christoph J Griessenauer  40 David S Liebeskind  42 Alessandro Pedicelli  43 Andrea Maria Alexandre  43 Illario Tancredi  44 Erwah Kalsoum  16 Boris Lubicz  45 Aman B Patel  5 Vitor Mendes Pereira  19 Max Wintermark  2 Adrien Guenego  45 Adam A Dmytriw  46   19 MAD-MT Investigators
Collaborators, Affiliations
Comparative Study

Endovascular therapy versus medical management in isolated anterior cerebral artery acute ischemic stroke: a multinational multicenter propensity score-weighted study

Hamza Adel Salim et al. J Neurointerv Surg. .

Abstract

Background: Isolated anterior cerebral artery occlusions (ACAo) in patients with acute ischemic stroke present significant challenges due to their rarity. The efficacy and safety of endovascular therapy (EVT) in comparison with best medical therapy (BMT) for ACAo remains unclear. This study aimed to assess the outcomes of these treatments.

Methods: This multinational, multicenter study analyzed data from the MAD-MT registry. Data were collected retrospectively from 37 sites across North America, Asia, and Europe. Inverse probability of treatment weighting (IPTW) was applied to balance confounding variables. The primary outcome was functional independence (modified Rankin Scale (mRS) scores of 0-2) at 90 days. Secondary outcomes included excellent outcomes (mRS 0-1), mortality at 90 days, and NIH Stroke Scale (NIHSS) score on day 1 post treatment.

Results: Of the 108 patients, 36 received BMT and 72 underwent EVT. The median age was 75 years, and 56% were male. At 90 days, 40% of patients achieved mRS 0-2, with no significant difference between EVT and BMT (38% vs 45%, p=0.46). Procedural success (mTICI 2b-3) was 91% in the EVT group, with a sICH rate of 2.9%. IPTW-adjusted analysis showed no significant difference between EVT and BMT for functional independence (OR 1.17, 95% CI 0.23 to 6.02, p=0.85), mortality (25% vs 21%, p=0.71) or day 1 NIHSS scores (Beta 2.2, 95% CI -0.51 to 4.8, p=0.11).

Conclusions: EVT showed high procedural success but did not significantly improve functional outcomes or mortality compared with BMT in patients with ACAo. Further randomized trials are needed to clarify EVT's role in ACAo.

Keywords: Stroke.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RWR serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Penumbra and Microvention, and receives stroke research grant funding from the National Institutes of Health, Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. AG reports consultancy for Rapid Medical and Phenox, not directly related to the present work. FC reports conflicts of interest with Medtronic, Balt Extrusion (consultant), ClinSearch (core lab), Penumbra, Stryker (payment for reading) and Artedrone (Board); all not directly related to the present work. NH received support from NINDS NS131756, NINR NR020231, and NINDS NS113844 during the conduct of the study. All unrelated to the present work. DSL is consultant as Imaging Core Lab to Cerenovus, Genentech, Medtronic, Stryker, Rapid Medical. LLLY reports advisory work for AstraZeneca, substantial support from NMRC Singapore and is a medical advisor for See-mode, Cortiro and Sunbird Bio, with equity in Ceroflo. All unrelated to the present work. CJG reports a proctoring agreement with Medtronic and research funding by Penumbra. GM reports conflicts of interest with Microvention Europe, Stryker Neurovascular, Balt, Sim and Cure (consulting), Medtronic, Johnson & Johnson, Penumbra, Bracco, and Phenox (paid lectures), all not directly related to the present work. ASP is a consultant for Medtronic Neurovascular, Stryker Neurovascular, Balt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical, he received research grants from NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular, and holds stocks in InNeuroCo, Agile, Perfuze, Galaxy and NTI. Dr Tjoumakaris is a consultant for Medtronic and Microvention (funds paid to institution, not personally). PJ is a consultant for Medtronic, Microvention and Cerus. BP reports consultancy Microvention, Stryker, Q’apel, and Nuvascular, all not directly related to the present work. JES has served as a consultant for AstraZeneca, and has received funding from the National Institutes of Health (R61NS135583), Viz.ai, Philips, and Medtronic. TNN reports Associate Editor of Stroke; advisory for Aruna Bio, Brainomix.

References

    1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. doi:10.1016/S1474-4422(21)00252-0 - DOI - PMC - PubMed
    1. Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected Global Trends in Ischemic Stroke Incidence, Deaths and Disability-Adjusted Life Years From 2020 to 2030. Stroke. 2023;54(5):1330–1339. doi:10.1161/STROKEAHA.122.040073 - DOI - PubMed
    1. Duloquin G, Graber M, Garnier L, et al. Incidence of Acute Ischemic Stroke With Visible Arterial Occlusion: A Population-Based Study (Dijon Stroke Registry). Stroke. 2020;51(7):2122–2130. doi:10.1161/STROKEAHA.120.029949 - DOI - PubMed
    1. Kumral E, Bayulkem G, Evyapan D, Yunten N. Spectrum of anterior cerebral artery territory infarction: clinical and MRI findings. Eur J Neurol. 2002;9(6):615–624. doi:10.1046/j.1468-1331.2002.00452.x - DOI - PubMed
    1. Arboix A, García-Eroles L, Sellarés N, Raga A, Oliveres M, Massons J. Infarction in the territory of the anterior cerebral artery: clinical study of 51 patients. BMC Neurol. 2009;9:30. doi:10.1186/1471-2377-9-30 - DOI - PMC - PubMed

LinkOut - more resources